2,145 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Perpetual Ltd

Perpetual Ltd bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 2,145 shares of the biopharmaceutical company’s stock, valued at approximately $1,656,000.

Other large investors have also recently bought and sold shares of the company. Aspiriant LLC bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $308,000. Bouchey Financial Group Ltd bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $255,000. Pacific Sage Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $238,000. Perigon Wealth Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 16.9% during the 4th quarter. Perigon Wealth Management LLC now owns 7,836 shares of the biopharmaceutical company’s stock valued at $6,048,000 after acquiring an additional 1,135 shares during the last quarter. Finally, Values Added Financial LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $215,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $761.85 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The stock has a 50 day simple moving average of $766.62 and a two-hundred day simple moving average of $713.93. The firm has a market cap of $80.54 billion, a P/E ratio of 18.33, a P/E/G ratio of 2.02 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business’s revenue was up 2.5% compared to the same quarter last year. During the same period last year, the firm posted $12.07 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a dividend of $0.94 per share. The ex-dividend date was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares in the company, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 5,274 shares of company stock valued at $4,142,738. Corporate insiders own 7.02% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: EYLEA HD (aflibercept) received FDA approval with extended dosing intervals up to five months for wAMD and DME — this can raise lifetime patient value, reduce treatment burden, and boost Regeneron’s retina revenue and competitive positioning. EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
• Positive Sentiment: Regeneron struck a strategic collaboration with TriNetX to access ~300 million de‑identified EHR records, giving it broader phenotypic linkage to its genomic/proteomic datasets — this should accelerate target discovery, improve clinical-trial design, and strengthen AI-driven drug development over time. Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
• Positive Sentiment: Analyst commentary and Zacks/Yahoo pieces highlight Regeneron’s strong earnings‑surprise history and factors that point to another potential beat — supporting short‑term investor optimism ahead of upcoming results. Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Regeneron told investors it expects to be excluded from the U.S. list facing proposed pharma tariffs — that reduces near‑term policy risk and potential margin pressure relative to peers. Regeneron says it expects to avoid new US pharma tariffs
• Neutral Sentiment: Piper Sandler has initiated coverage of Regeneron (details of the call/rating were not in the summary) — coverage can increase attention/liquidity but the impact depends on the firm’s stated rating and model. Piper Sandler Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on REGN shares. Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Oppenheimer reiterated an “outperform” rating and set a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research report on Monday, March 2nd. Finally, Piper Sandler initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They set an “overweight” rating and a $875.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $804.70.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.